Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas

Anti-Cancer Drugs

Volumn 20, Issue 1, 2009, Pages 15-20

  Grenader, Tal ^a   Goldberg, Anthony ^a   Hadas Halperin, Irit ^a   Gabizon, Alberto ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Cardiotoxicity; Pegylated liposomal doxorubicin; Soft tissue sarcomas

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ERYTHEMA; ESOPHAGUS ULCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIPOSOMAL DELIVERY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; SOFT TISSUE SARCOMA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 57349099427     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283198058     Document Type: Article

References (19)

1. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcomac can still be considered standard care. Oncologist 2005; 10:833-841.
2. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987; 5:840-850.
3. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36:61-67.
4. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008; 109:323-328.
5. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62:226-229.
6. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004; 31: 161-181.
7. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycolderivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10:703-708.
8. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res 1994; 54:987-992.
9. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7:243-254.
10. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethyleneglycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36:55-63.
11. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 2008; 8:21-32.
12. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma; a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870-877.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
14. Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, et al. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer 2004; 91:1639-1644.
15. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs 2000; 18:253-259.
16. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21:167-176.
17. Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96:749-752.
18. Koukourakis Ml, Koukouraki S, Giatromanolaki A. Kakolyris S. Georgoulias V, Velidaki A, el al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000; 39:207-211.
19. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Pipemo-Neumann S, et al. Groupe Sarcome Francais. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119:706-711.